Oral presentations
​
​1596O Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials
Grist E, ESMO 2024
https://doi.org/10.1016/j.annonc.2024.08.1677
1767MO - External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived model in high-risk localized (M0)/metastatic (M1) prostate cancer (PCa) starting androgen deprivation therapy (ADT) in the docetaxel (Doc) or abiraterone (AAP) phase III STAMPEDE trials​
Parker CTA, ESMO 2023
​​​
Discovery and qualification of multi-modality biomarkers for men starting long-term androgen deprivation therapy in the STAMPEDE clinical trial
Grist E, PCF 29th Annual Scientific Retreat Young Investigator Session 2022
​
LBA62 - Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol
Attard G, et al. ESMO 2022
​
1358O - Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial
Parry MA, et al. ESMO 2022
​
LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol
Attard G, et al. ESMO 2021
​
Poster presentations
​​
​
1656TiP The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)
Howlett S, Kayani M, et al. ESMO 2024
https://doi.org/10.1016/j.annonc.2024.08.1737
​
Abstract 973: Plasma androgen receptor (AR) copy number gain at progression in patients randomized in the STAMPEDE phase 3 abiraterone acetate, prednisolone (AAP) and enzalutamide (ENZ) trial: An ancillary biomarker study
Leone G, et al. AACR 2024
https://doi.org/10.1158/1538-7445.AM2024-973
​​
Ismail M, et al. AACR 2024
https://doi.org/10.1158/1538-7445.AM2024-7568
​​
1809P Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
Brighi N, et al. ESMO 2023
https://doi.org/10.1016/j.annonc.2023.09.2757
​
PCF SELECT targeted genome sequencing of Plasma DNA at progression on androgen deprivation therapy alone or with abraterone and enzalutamide: an ancillary study of the STAMPEDE trial
Leone G, et al. PCF 29th Annual Scientific Retreat 2022
​​
High-sensitivity tracking of copy number alterations and single nucleotide variants in sequential plasma DNA collections from metastatic prostate cancer (mPC) patients
Trujillo B. and Vainauskas O., et al. EACR Liquid Biopsies 2022
5021 Copy number profiles of primary tumors for risk stratification of advanced prostate cancer: A biomarker study embedded in the multicenter STAMPEDE trial
Grist E, et al. ASCO 2021
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.5021
​
P - 182 Tumour Infiltrating Lymphocytes assessment in the STAMPEDE cohort: association of brisk inflammation with high grade histology
Mendes L, et al. EACR-AACR-ASPIC Tum Microenvironment 2020
​
153 Multiregion expression profiling of prostate cancer from men randomized in the STAMPEDE trial: Stage I results of a multistage biomarker analysis
Grist E, et al. GU ASCO 2020
https://meetinglibrary.asco.org/record/183430/abstract
​
39 Copy number profiling of STAMPEDE trial patients to improve targeting of existing therapies for advanced hormone-sensitive prostate cancer
Grist E, et al. EACR Cancer Genomics Conference 2019
​
88 Whole genome expression analysis of diagnostic patient samples enrolled in the STAMPEDE clinical trial in advanced prostate cancer
Parry M, et al. EACR Cancer Genomics Conference 2019
​
29P - Implementing molecular characterisation of prostate cancer tissue from patients recruited to the multi-centre STAMPEDE trial: The STRATOSPHERE consortium
Grist E, et al. MAP. 2018
https://www.sciencedirect.com/science/article/pii/S0923753419323804
​